Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-10-12FDA Approved: VIGABATRIN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Vigabatrin by Aurobindo Pharma Limited under ANDA213899.
-
FDA approval · 2022-10-12FDA Approved: VIGABATRIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA granted supplemental approval for Vigabatrin from Amneal Pharmaceuticals NY LLC under ANDA210042, enabling a revised/expanded approval f…
-
FDA approval · 2022-10-12FDA Approved: VIGABATRIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for Vigabatrin submitted by Ascend Laboratories, LLC.
-
FDA approval · 2022-10-12FDA Approved: VIGABATRIN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Vigabatrin submitted by Aurobindo Pharma Limited, indicating regulatory action to authorize this…
-
FDA approval · 2022-10-12FDA Approved: VIGABATRIN — Supplemental Application (Hikma Pharmaceuticals USA Inc)
FDA approved a supplemental application for Vigabatrin submitted by Hikma Pharmaceuticals USA Inc, representing an additional regulatory act…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-10-12FDA Approved: VIGABATRIN — Supplemental Application (Edenbridge Pharmaceuticals LLC.)
FDA approved a supplemental application for Vigabatrin from Edenbridge Pharmaceuticals LLC. under ANDA 215109.
-
FDA approval · 2022-10-06FDA Approved: CARBAMAZEPINE — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' generic carbamazepine under Original Application ANDA214277.
-
FDA approval · 2022-10-03FDA Approved: BRIVARACETAM — Original Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a generic version of brivaracetam (BRIVARACETAM) from Zydus Pharmaceuticals USA Inc. under Original Application ANDA214501.
-
FDA approval · 2022-09-30FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Vimpat (lacosamide) filed by UCB, Inc., signaling an FDA-approved expansion or modification to t…
-
FDA approval · 2022-09-30FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., resulting in a labeling update for the drug.
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME) [NA]
Completed clinical trial TIME studied targeted self-management for epilepsy and serious mental illness; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-09-23Clinical Trial Update: Behavioral Economics and Adherence in Teens (BEAT!) [NA]
Completed clinical trial BEAT! investigating behavioral economics and adherence in teens for epilepsy, with results posted in 2022.
-
FDA approval · 2022-09-19FDA Approved: LACOSAMIDE — Original Application (Gland Pharma Limited)
FDA approved an original application for lacosamide from Gland Pharma Limited to market a generic lacosamide product. The approval covers it…
-
FDA approval · 2022-09-14FDA Approved: LACOSAMIDE — Original Application (XLCare Pharmaceuticals Inc.)
The FDA approves XLCare Pharmaceuticals' original ANDA for lacosamide, making a generic lacosamide available in the market.
-
CLINICAL_TRIALS trial_result · 2022-09-08Clinical Trial Update: CX-8998 for Absence Seizures [Phase 2]
Phase 2 clinical trial of CX-8998 for epilepsy (absence seizures) has completed with results posted.
-
FDA approval · 2022-09-07FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Dilantin to authorize an extended phenytoin sodium formulation. This product is manufactured…
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601 [Phase 2]
A Phase 2 clinical trial update describes a treatment use protocol for subjects continuing from an open-label extension (0601) in epilepsy, …
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: Microelectrodes in Epilepsy [NA]
Clinical trial update on microelectrodes for epilepsy has completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies [Phase 2]
Phase 2 open-label trial of ganaxolone in children with PCDH19 female pediatric epilepsy and other rare genetic epilepsies completed with re…
-
FDA approval · 2022-09-07FDA Approved: VIGABATRIN — Original Application (Novadoz Pharmaceuticals LLC)
The FDA approved the original Abbreviated New Drug Application for vigabatrin from Novadoz Pharmaceuticals LLC, yielding a generic version o…
-
FDA approval · 2022-08-30FDA Approved: OXCARBAZEPINE — Original Application (Advagen Pharma Ltd)
FDA approves the original application for oxcarbazepine from Advagen Pharma Ltd, granting approval for a generic version of the antiseizure …
-
CLINICAL_TRIALS trial_result · 2022-08-29Clinical Trial Update: Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy [Phase 3]
Open-label long-term Phase 3 study of adjunctive brivaracetam in pediatric epilepsy completed and results posted.
-
FDA approval · 2022-08-29FDA Approved: VIGABATRIN — Original Application (Hikma Pharmaceuticals USA Inc)
FDA approved Hikma's generic Vigabatrin under an Original Application (ANDA 213104). This notice confirms approval of a generic Vigabatrin p…
-
FDA approval · 2022-08-26FDA Approved: LACOSAMIDE — Original Application (ANI Pharmaceuticals, Inc.)
FDA approved ANI Pharmaceuticals' Original Abbreviated New Drug Application for lacosamide, authorizing the marketing of a generic lacosamid…
-
FDA approval · 2022-08-25FDA Approved: ETHOSUXIMIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for Ethosuximide submitted by Strides Pharma Science Limited.